{"id":"NCT03499873","sponsor":"Actavis Inc.","briefTitle":"Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension","officialTitle":"A Randomized, Multicenter, Double Masked, Placebo Controlled, Parallel Group, Bioequivalence Study to Evaluate the Clinical Equivalence and Safety of Nepafenac 0.3% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Actavis LLC) With IlevroTM (Nepafenac Ophthalmic Suspension), 0.3% of Alcon Laboratories, Inc. for the Treatment of Pain and Inflammation Associated With Cataract Surgery.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-28","primaryCompletion":"2018-10-31","completion":"2018-12-18","firstPosted":"2018-04-17","resultsPosted":"2021-02-16","lastUpdate":"2021-02-16"},"enrollment":448,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cataract"],"interventions":[{"type":"DRUG","name":"Nepafenac 0.3% Oph Susp","otherNames":[]},{"type":"DRUG","name":"Placebos","otherNames":[]},{"type":"DRUG","name":"Nepafenac 0.3% Oph Susp (reference)","otherNames":[]}],"arms":[{"label":"Nepafenac 0.3% Opthalmic Suspension","type":"EXPERIMENTAL"},{"label":"Ilevro 0.3% Opthalmic Suspension","type":"ACTIVE_COMPARATOR"},{"label":"Placebo (vehicle) Opthalmic Suspension","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic suspension), 0.3% of Alcon Laboratories, Inc. for the treatment of pain and inflammation associated with cataract surgery.","primaryOutcome":{"measure":"Cure at Day 14","timeFrame":"14 days","effectByArm":[{"arm":"Nepafenac 0.3% Opthalmic Suspension","deltaMin":94,"sd":null},{"arm":"Ilevro 0.3% Opthalmic Suspension","deltaMin":97,"sd":null},{"arm":"Placebo (Vehicle) Opthalmic Suspension","deltaMin":24,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":"0.0005"},{"comp":"OG001 vs OG002","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":175},"commonTop":["Headache","Blood glucose increased","Intraocular pressure increased","Eye pain","Anterior chamber inflammation"]}}